nivolumab,ipilimumab
bms
['nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ipilimumab', 'nivo']
latinx patients with #mrcc demonstrated shorter progression-free survival than non-latinx patients after #nivolumab-plus-#ipilimumab treatment at a tertiary care center, according to a new analysis presented at #gu23. read more: 
GU Oncology Now delivers the latest news in therapeutics, clinical trials, conference coverage, and important advancements in the genitourinary oncology field.